Xeris Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-0.452; its P/E ratio is -4.93; Xeris Pharmaceuticals is scheduled to report earnings on May 8, 2024, and the estimated EPS forecast is $-0.10. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 48.32M	-	$ 33.20M	$ 33.14M	$ 29.73M
Gross Profit	$ 40.12M	-	$ 33.20M	$ 26.85M	$ 24.46M
EBIT	$ -5.68M	-	$ -10.62M	$ -8.90M	$ -18.18M
EBITDA	-	-	$ -7.27M	$ -5.40M	$ -15.11M
Net Income Common Stockholders	$ -12.19M	-	$ -16.83M	$ -12.93M	$ -21.83M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 65.97M	$ 80.67M	$ 95.10M	$ 121.97M	$ 93.43M
Total Assets	$ 327.78M	$ 328.78M	$ 321.36M	$ 344.52M	$ 303.02M
Total Debt	$ 227.94M	$ 224.99M	$ 198.42M	$ 198.06M	$ 138.51M
Net Debt	$ 161.97M	$ 144.32M	$ 103.31M	$ 76.09M	$ 45.07M
Total Liabilities	$ 323.92M	$ 315.14M	$ 291.31M	$ 299.33M	$ 247.98M
Stockholders Equity	$ 3.87M	$ 13.69M	$ 30.05M	$ 45.19M	$ 55.04M
Cash Flow	-
Free Cash Flow	-	-	$ -26.38M	$ -16.25M	$ -17.93M
Operating Cash Flow	-	-	$ -26.14M	$ -16.12M	$ -17.75M
Investing Cash Flow	-	-	$ -43.98M	$ 9.17M	$ 6.71M
Financing Cash Flow	-	-	$ -863.00K	$ 49.16M	$ -187.00K

Currency in USD

Xeris Pharmaceuticals Earnings and Revenue History

Income Statement >

Xeris Pharmaceuticals Debt to Assets

Balance Sheet >

Xeris Pharmaceuticals Cash Flow

Cash Flow >

Xeris Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing